Table 1. Demographic and baseline characteristics of enrolled patients.
| Variables | R20 (n=132) | RE10/10 (n=126) | Total (n=258) | p-value | |
|---|---|---|---|---|---|
| Male, No. (%) | 104 (78.8) | 91 (72.2) | 195 (75.6) | 0.220* | |
| Age (yr), median [Min, Max] | 63.5, [25.0, 74.0] | 63.5, [39.0, 75.0] | 63.5, [25.0, 75.0] | 0.478† | |
| Current smoker, No. (%) | 30 (22.7) | 26 (20.6) | 56 (21.7) | 0.684* | |
| Height (cm), median [Min, Max] | 165.0, [146.0, 185.0] | 165.0, [141.0, 182.0] | 165.0, [141.0, 185.0] | 0.465† | |
| Weight (kg), median [Min, Max] | 70.8, [44.0, 121.1] | 68.8, [46.0, 95.7] | 69.8, [44.0, 121.1] | 0.546† | |
| Duration of hypercholesterolemia (mon), median [Min, Max] | 58.5, [0.0, 247] | 61.0, [1.0, 253.0] | 59.0, [0.0, 253.0] | 0.821† | |
| Diabetes mellitus | 44 (33.3) | 40 (31.8) | 84 (32.6) | 0.786* | |
| Hypertension | 69 (52.3) | 63 (50.0) | 132 (51.2) | 0.810* | |
| Hypothyroidism | 3 (2.3) | 5 (4.0) | 8 (3.1) | 0.492* | |
| Clinical indications, No. (%) | |||||
| Acute myocardial infarction | 18 (13.6) | 27 (21.4) | 45 (17.4) | 0.138* | |
| Angina pectoris | 46 (34.9) | 29 (23.0) | 75 (29.1) | 0.051* | |
| Angina unstable | 36 (27.3) | 46 (36.5) | 82 (31.8) | 0.145* | |
R20, high intensity statin group which received 20 mg of rosuvastatin once daily; RE10/10, combination therapy group which received 10 mg rosuvastatin and 10 mg ezetimibe once daily.
*χ2 test; †Wilcoxon rank sum test.